163 related articles for article (PubMed ID: 10815930)
1. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model.
Fonsatti E; Jekunen AP; Kairemo KJ; Coral S; Snellman M; Nicotra MR; Natali PG; Altomonte M; Maio M
Clin Cancer Res; 2000 May; 6(5):2037-43. PubMed ID: 10815930
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
3. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
Seon BK; Matsuno F; Haruta Y; Kondo M; Barcos M
Clin Cancer Res; 1997 Jul; 3(7):1031-44. PubMed ID: 9815781
[TBL] [Abstract][Full Text] [Related]
4. Perfusion of 99Tcm-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target.
Costello B; Li C; Duff S; Butterworth D; Khan A; Perkins M; Owens S; Al-Mowallad AF; O'Dwyer S; Kumar S
Int J Cancer; 2004 Apr; 109(3):436-41. PubMed ID: 14961584
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy.
Burrows FJ; Derbyshire EJ; Tazzari PL; Amlot P; Gazdar AF; King SW; Letarte M; Vitetta ES; Thorpe PE
Clin Cancer Res; 1995 Dec; 1(12):1623-34. PubMed ID: 9815965
[TBL] [Abstract][Full Text] [Related]
6. CD105 is important for angiogenesis: evidence and potential applications.
Duff SE; Li C; Garland JM; Kumar S
FASEB J; 2003 Jun; 17(9):984-92. PubMed ID: 12773481
[TBL] [Abstract][Full Text] [Related]
7. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies.
Matsuno F; Haruta Y; Kondo M; Tsai H; Barcos M; Seon BK
Clin Cancer Res; 1999 Feb; 5(2):371-82. PubMed ID: 10037187
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas.
Ding I; Sun JZ; Fenton B; Liu WM; Kimsely P; Okunieff P; Min W
Cancer Res; 2001 Jan; 61(2):526-31. PubMed ID: 11212245
[TBL] [Abstract][Full Text] [Related]
9. Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers.
di Tomaso E; Capen D; Haskell A; Hart J; Logie JJ; Jain RK; McDonald DM; Jones R; Munn LL
Cancer Res; 2005 Jul; 65(13):5740-9. PubMed ID: 15994949
[TBL] [Abstract][Full Text] [Related]
10. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin.
Takahashi N; Kawanishi-Tabata R; Haba A; Tabata M; Haruta Y; Tsai H; Seon BK
Clin Cancer Res; 2001 Mar; 7(3):524-32. PubMed ID: 11297243
[TBL] [Abstract][Full Text] [Related]
11. Lack of specificity of endoglin expression for tumor blood vessels.
Balza E; Castellani P; Zijlstra A; Neri D; Zardi L; Siri A
Int J Cancer; 2001 Nov; 94(4):579-85. PubMed ID: 11745447
[TBL] [Abstract][Full Text] [Related]
12. Endoglin (CD105): a target for anti-angiogenetic cancer therapy.
Fonsatti E; Altomonte M; Arslan P; Maio M
Curr Drug Targets; 2003 May; 4(4):291-6. PubMed ID: 12699349
[TBL] [Abstract][Full Text] [Related]
13. Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies.
Fonsatti E; Del Vecchio L; Altomonte M; Sigalotti L; Nicotra MR; Coral S; Natali PG; Maio M
J Cell Physiol; 2001 Jul; 188(1):1-7. PubMed ID: 11382917
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies.
Tabata M; Kondo M; Haruta Y; Seon BK
Int J Cancer; 1999 Aug; 82(5):737-42. PubMed ID: 10417773
[TBL] [Abstract][Full Text] [Related]
15. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels.
Fonsatti E; Altomonte M; Nicotra MR; Natali PG; Maio M
Oncogene; 2003 Sep; 22(42):6557-63. PubMed ID: 14528280
[TBL] [Abstract][Full Text] [Related]
16. Endoglin (CD105) expression in angiogenesis of colon cancer: analysis using tissue microarrays and comparison with other endothelial markers.
Minhajat R; Mori D; Yamasaki F; Sugita Y; Satoh T; Tokunaga O
Virchows Arch; 2006 Feb; 448(2):127-34. PubMed ID: 16177881
[TBL] [Abstract][Full Text] [Related]
17. [The immunohistochemical expression of CD105 is a marker for high metastatic risk and worse prognosis in breast cancers].
Charpin-Taranger C; Dales JP; Garcia S; Andrac-Meyer L; Ramuz O; Carpentier-Meunier S; Bonnier P
Bull Acad Natl Med; 2003; 187(6):1129-45; discussion 1145-6. PubMed ID: 14978873
[TBL] [Abstract][Full Text] [Related]
18. Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma.
Altomonte M; Montagner R; Fonsatti E; Colizzi F; Cattarossi I; Brasoveanu LI; Nicotra MR; Cattelan A; Natali PG; Maio M
Br J Cancer; 1996 Nov; 74(10):1586-91. PubMed ID: 8932339
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
